Publications by authors named "Mehreen S Datoo"

Claim this Profile
R
R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.
Elizabeth Kibwana, Caroline Bundi, Domtila Kimani, Lydia Nyamako, Kelvias Keter, Mehreen S Datoo

Front Immunol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Navin Venkatraman, Daniel Silman, Duncan Bellamy, Lisa Stockdale, Georgina Bowyer, Mehreen S Datoo

Lancet Microbe· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Navin Venkatraman, Alfred B Tiono, Georgina Bowyer, Duncan G Bellamy, Lisa K Stockdale, Mehreen S Datoo

Lancet Microbe· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Mehreen S Datoo, Adrian V S Hill, Emma Beaumont, John Bradley

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Nora Schmit, Hillary M Topazian, H Magloire Natama, Duncan Bellamy, Ousmane Traoré, Mehreen S Datoo

Lancet Infect Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Mehreen S Datoo, Alassane Dicko, Halidou Tinto, Jean-Bosco Ouédraogo, Mainga Hamaluba

Lancet· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Samuel Sang, Mehreen S Datoo, Edward Otieno, Charles Muiruri, Duncan Bellamy

Wellcome Open Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Mehreen S Datoo, Hamtandi Magloire Natama, Athanase Somé, Duncan Bellamy, Ousmane Traoré

Lancet Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Andrés Noé, Mehreen S Datoo, Amy Flaxman, Mohammad Ali Husainy, Daniel Jenkin

Front Immunol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass administration of azithromycin reduces childhood mortality in Niger.
Sarah Murphy, Mehreen S Datoo

Arch Dis Child Educ Pract Ed· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Mehreen S Datoo, Magloire H Natama, Athanase Somé, Ousmane Traoré, Toussaint Rouamba

Lancet· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis